Ovarian cancer endpoints workshop
Executive Summary
FDA and the American Society for Clinical Oncology, in conjunction with FDA's Oncologic Drugs Advisory Committee, will hold a public workshop on ovarian cancer endpoints April 26 at the Marriott Hotel in North Bethesda, Md. FDA plans to issue a guidance document from the workshop findings. The agency has previously held meetings on lung, colorectal, prostate and brain cancer endpoints (1"The Pink Sheet" Feb. 6, 2006, p. 15). [Editor's note: To 2watch a webcastor order a video/DVD of this or any other meeting, visit FDAAdvisoryCommittee.com.]...
You may also be interested in...
Progression-Free Survival Is Meaningful Endpoint For Glioma Trials
Progression free survival assessed at six months should be considered as a meaningful surrogate endpoint in evaluating primary brain tumor clinical trials for accelerated approval, a panel assembled by FDA agreed
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.